{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:30:17Z","timestamp":1786739417797,"version":"build-2736575974"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The world is currently facing a pandemic triggered by the novel corona virus (SARS \u2013 CoV2), which causes a highly infectious infection that predominantly affects the lungs, resulting in a variety of clinical symptoms some cases may be asymptomatic while others may result in to severe respiratory disorder, if the infection is left unattended it may result in multi-organ failure and eventually death of the patient. The transmission of infection is by droplet and fomites of the infected person. The incubation period of virus is from 2 to 14 days. Most common symptoms resemble flu-like but later progress to pneumonia along with dyspnoea and worsening of oxygen saturation, thus requiring ventilator support. The diagnostic modalities include Reverse transcriptase real time PCR (Quantitative Reverse transcriptase polymerase chain reaction) which is recommended method used for diagnosis of the COVID-19 infection using oro-pharyngeal or nasopharyngeal swabs of the patients. Recently serological tests for antigen and antibody detection has been approved by ICMR. Till now, nine COVID-19 vaccines are granted emergency approval for prevention and for the management of infection symptomatic and supportive measures are being adopted. Globally major pharmaceutical firms are engrossed for development of a potent vaccine candidate. This review highlights on various vaccine candidates under clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jfmpc.jfmpc_1570_20","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T11:10:32Z","timestamp":1627557032000},"page":"2457-2466","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["A comprehensive insight on the COVID-19 vaccine candidates"],"prefix":"10.4103","volume":"10","author":[{"given":"Anu","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi Prakash","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimplejeet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ria","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surjit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20240828","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","article-title":"Structure, function, and evolution of coronavirus spike proteins","volume":"3","author":"Li","year":"2016","journal-title":"Annu Rev Virol"},{"key":"R2-5-20240828","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1586\/erv.10.139","article-title":"IMOJEV(\u00ae): A Yellow fever virus-based novel Japanese encephalitis vaccine","volume":"9","author":"Appaiahgari","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"R3-5-20240828","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3389\/fphar.2020.00937","article-title":"A snapshot of the global race for vaccines targeting SARS-CoV-2 and the COVID-19 pandemic","volume":"11","author":"Funk","year":"2020","journal-title":"Front Pharmacol"},{"key":"R4-5-20240828","first-page":"S9","article-title":"SARS: Epidemiology","volume":"8 Suppl","author":"Chan-Yeung","year":"2003","journal-title":"Respirology"},{"key":"R5-5-20240828","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1017\/S0025727300000107","article-title":"Variolation, vaccination and popular resistance in early colonial south India","volume":"48","author":"Brimnes","year":"2004","journal-title":"Med Hist"},{"key":"R6-5-20240828","doi-asserted-by":"crossref","first-page":"e029617","DOI":"10.1136\/bmjopen-2019-029617","article-title":"Effects of vaccines in protecting against Ebola virus disease: Protocol for a systematic review","volume":"9","author":"Mathebula","year":"2019","journal-title":"BMJ Open"},{"key":"R7-5-20240828","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4103\/0974-777X.77299","article-title":"Fundamentals of vaccine immunology","volume":"3","author":"Clem","year":"2011","journal-title":"J Glob Infect Dis"},{"key":"R8-5-20240828","doi-asserted-by":"crossref","first-page":"46","DOI":"10.7774\/cevr.2015.4.1.46","article-title":"Clinical vaccine development","volume":"4","author":"Han","year":"2015","journal-title":"Clin Exp Vaccine Res"},{"key":"R9-5-20240828","doi-asserted-by":"crossref","first-page":"982","DOI":"10.3389\/fimmu.2017.00982","article-title":"Immunobiography and the heterogeneity of immune responses in the elderly: A focus on inflammaging and trained immunity","volume":"8","author":"Franceschi","year":"2017","journal-title":"Front Immunol"},{"key":"R10-5-20240828","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1038\/nm1143","article-title":"Severe acute respiratory syndrome","volume":"10","author":"Peiris","year":"2004","journal-title":"Nat Med"},{"key":"R11-5-20240828","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0022-2836(03)00865-9","article-title":"Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage","volume":"331","author":"Snijder","year":"2003","journal-title":"J Mol Biol"},{"key":"R12-5-20240828","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.virusres.2014.11.013","article-title":"Receptor-binding domain-based subunit vaccines against MERS-CoV","volume":"202","author":"Zhang","year":"2015","journal-title":"Virus Res"},{"key":"R13-5-20240828","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.imlet.2004.06.014","article-title":"Immunogenicity of SARS inactivated vaccine in BALB\/c mice","volume":"95","author":"Xiong","year":"2004","journal-title":"Immunol Lett"},{"key":"R14-5-20240828","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbrc.2004.10.052","article-title":"Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry","volume":"325","author":"He","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"R15-5-20240828","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3201\/eid1107.050219","article-title":"SARS vaccine development","volume":"11","author":"Jiang","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"R16-5-20240828","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.virol.2005.01.042","article-title":"Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein","volume":"334","author":"Bisht","year":"2005","journal-title":"Virology"},{"key":"R17-5-20240828","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(04)16501-X","article-title":"Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS","volume":"363","author":"Bukreyev","year":"2004","journal-title":"Lancet"},{"key":"R18-5-20240828","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1128\/JVI.79.3.1906-1910.2005","article-title":"Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system","volume":"79","author":"Wang","year":"2005","journal-title":"J Virol"},{"key":"R19-5-20240828","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1099\/0022-1317-74-4-745","article-title":"Identification of antigenic sites mediating antibody-dependent enhancement of feline infectious peritonitis virus infectivity","volume":"74","author":"Olsen","year":"1993","journal-title":"J Gen Virol"},{"key":"R20-5-20240828","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1128\/JVI.79.5.2678-2688.2005","article-title":"Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region","volume":"79","author":"Chen","year":"2005","journal-title":"J Virol"},{"key":"R21-5-20240828","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nbt.1635","article-title":"Rationalizing the development of live attenuated virus vaccines","volume":"28","author":"Lauring","year":"2010","journal-title":"Nat Biotechnol"},{"key":"R22-5-20240828","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2020.4596","article-title":"Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review)","volume":"46","author":"Calina","year":"2020","journal-title":"Int J Mol Med"},{"key":"R23-5-20240828","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/21655979.2016.1191707","article-title":"Recent advances in the production of recombinant subunit vaccines in Pichia pastoris","volume":"7","author":"Wang","year":"2016","journal-title":"Bioengineered"},{"key":"R24-5-20240828","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines-A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"R25-5-20240828","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","article-title":"mRNA as a transformative technology for vaccine development to control infectious diseases","volume":"27","author":"Maruggi","year":"2019","journal-title":"Mol Ther"},{"key":"R26-5-20240828","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1586\/14760584.2016.1124762","article-title":"Molecular mechanisms for enhanced DNA vaccine immunogenicity","volume":"15","author":"Li","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"R27-5-20240828","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"Rold\u00e3o","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"R28-5-20240828","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/imr.12098","article-title":"Advances in antiviral vaccine development","volume":"255","author":"Graham","year":"2013","journal-title":"Immunol Rev"},{"key":"R29-5-20240828","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40011-011-0014-9","article-title":"Viral vaccines in India: An overview","volume":"82","author":"Bharati","year":"2012","journal-title":"Proc Natl Acad Sci India Sect B Biol Sci"},{"key":"R30-5-20240828","first-page":"002","article-title":"Japanese encephalitis vaccines","volume":"S1","author":"McArthur","year":"2011","journal-title":"J Bioterror Biodef"},{"key":"R31-5-20240828","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/j.vaccine.2011.01.058","article-title":"Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO\u00ae, IC51","volume":"29","author":"Eder","year":"2011","journal-title":"Vaccine"},{"key":"R32-5-20240828","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4161\/hv.26549","article-title":"Yellow fever vaccine: An effective vaccine for travelers","volume":"10","author":"Verma","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"R33-5-20240828","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Thanh Le","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"R34-5-20240828","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/21645515.2015.1093263","article-title":"Primary vaccine failure to routine vaccines: Why and what to do","volume":"12","author":"Wiedermann","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"R35-5-20240828","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.micinf.2020.02.006","article-title":"Is COVID-19 receiving ADE from other coronaviruses","volume":"22","author":"Tetro","year":"2020","journal-title":"Microbes Infect"},{"key":"R36-5-20240828","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.4161\/hv.24696","article-title":"The effect of ageing of the immune system on vaccination responses","volume":"9","author":"Lord","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"R37-5-20240828","first-page":"637","article-title":"Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues (Review)","volume":"52","author":"Boda","year":"2018","journal-title":"Int J Oncol"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1570_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:28:49Z","timestamp":1786735729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1570_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1570_20","relation":{},"ISSN":["2249-4863"],"issn-type":[{"value":"2249-4863","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}